Molecular assembler

Molecular Assemblies Receives the 2023 BioServices Innovation of the Year Award from BioTech Breakthrough Awards Program

Retrieved on: 
Mercredi, novembre 8, 2023
Science, Gene editing, Biomedical Research, Molecular biology, Medicine, Biotechnology, Mutagenesis, Protein engineering, Oligonucleotide, Research, NGS, Antibody, Messenger, Molecular assembler, SAN, DNA, Fine chemical, CRISPR

SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced it has been awarded BioServices Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry. This year's program attracted more than 1,500 nominations from over 12 different countries throughout the world.

Key Points: 
  • "Molecular Assemblies was founded with a vision to deliver long, pure oligonucleotides that power new breakthroughs in biomedical research and beyond," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "With our first placements of enzymatically synthesized oligos in customer's hands, this award from BioTech Breakthrough drives home that our vision is now a reality."
  • "We are excited to receive this BioTech Breakthrough Award, which recognizes the companies that have set themselves apart from their competitors," said Phil Paik, Ph.D., Chief Technology Officer of Molecular Assemblies.
  • "Congratulations to Molecular Assemblies for being the 'BioServices Innovation of the Year' winner.

DNA Data Storage Market worth $3,348 million by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Lundi, novembre 6, 2023
Cloud, Sequence, FRAM, BGI, Twist Bioscience, HMC, Volatile memory, Bay, Biotechnology, EEPROM, Region, NvSRAM, NAND, MRAM, NRAM, Research, Investment, Illumina, Inc., NAS, Enterprise, Genomics, Thermo Fisher Scientific, 3D NAND, University, 3D XPoint, Holographic Data Storage System, Cloud computing, PMC, STT-MRAM, Oxford Nanopore Technologies, HBM, Agilent Technologies, EPROM, Quantum Corporation, Consumer electronics, Molecular assembler, Resistive random-access memory, Longevity, DNA, Computer data storage, Catalog, Health care, Microsoft, Automotive industry

Cloud based DNA data storage to hold the largest share of the DNA data storage market during the forecast period.

Key Points: 
  • Cloud based DNA data storage to hold the largest share of the DNA data storage market during the forecast period.
  • Sequence-based DNA data storage segment is expected to be the fastest growing market of the DNA data storage market during the forecast period.
  • Sequence-based DNA data storage is a type of DNA data storage in which data is encoded in the sequence of DNA bases.
  • However, sequence-based DNA data storage is expected to be less durability and more expensive in comparison to structure-based DNA data storage.

DNA Data Storage Market worth $3,348 million by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Lundi, novembre 6, 2023
Cloud, Sequence, FRAM, BGI, Twist Bioscience, HMC, Volatile memory, Bay, Biotechnology, EEPROM, Region, NvSRAM, NAND, MRAM, NRAM, Research, Investment, Illumina, Inc., NAS, Enterprise, Genomics, Thermo Fisher Scientific, 3D NAND, University, 3D XPoint, Holographic Data Storage System, Cloud computing, PMC, STT-MRAM, Oxford Nanopore Technologies, HBM, Agilent Technologies, EPROM, Quantum Corporation, Consumer electronics, Molecular assembler, Resistive random-access memory, Longevity, DNA, Computer data storage, Catalog, Health care, Microsoft, Automotive industry

Cloud based DNA data storage to hold the largest share of the DNA data storage market during the forecast period.

Key Points: 
  • Cloud based DNA data storage to hold the largest share of the DNA data storage market during the forecast period.
  • Sequence-based DNA data storage segment is expected to be the fastest growing market of the DNA data storage market during the forecast period.
  • Sequence-based DNA data storage is a type of DNA data storage in which data is encoded in the sequence of DNA bases.
  • However, sequence-based DNA data storage is expected to be less durability and more expensive in comparison to structure-based DNA data storage.

Molecular Assemblies Ships First Enzymatically Synthesized Oligonucleotides

Retrieved on: 
Mardi, mars 14, 2023
SAN, Molecular assembler, Biotechnology, Research, DNA, FES, Gene editing, Protein engineering, Fine chemical, CRISPR

SAN DIEGO, March 14, 2023 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced it has shipped the first enzymatically synthesized oligonucleotides to top biotechnology, academic, and synthetic biology researchers, delivered as part of a key customer program.

Key Points: 
  • SAN DIEGO, March 14, 2023 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced it has shipped the first enzymatically synthesized oligonucleotides to top biotechnology, academic, and synthetic biology researchers, delivered as part of a key customer program.
  • "With the achievement of this significant commercial milestone, we are proving that fully enzymatic synthesis can deliver the DNA that customers want today, without compromise," said Michael J. Kamdar, President and CEO of Molecular Assemblies.
  • Long, pure single-stranded oligonucleotides are a central component for many emerging applications including CRISPR gene editing tools used in research discovery, therapeutic development and protein engineering.
  • Molecular Assemblies' Key Customer Program provides select researchers priority access to long, custom oligonucleotides synthesized with the company's FES technology.

Molecular Assemblies Appoints Mark Nibbe Vice President of Operations

Retrieved on: 
Mardi, décembre 6, 2022
Aurora, Aurora Biosciences, Therapy, UC, Publication, University of California, San Diego, FES, DNA, Synthetic biology, Precision medicine, Reading, Multimedia, Engineering, CRISPR, Arthur Nibbs, Electronics, SAN, Molecular assembler, Management, Fine chemical, Illumina, Operation

SAN DIEGO, Dec. 6, 2022 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the appointment of Mark Nibbe as Vice President, Operations.

Key Points: 
  • SAN DIEGO, Dec. 6, 2022 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the appointment of Mark Nibbe as Vice President, Operations.
  • "Mark brings deep technical experience and leadership vision to enable new products and manufacturing capabilities by building the operational ecosystem from validated processes to nimble, collaborative teams," said Michael J. Kamdar, President and CEO of Molecular Assemblies.
  • "We welcome Mark as Molecular Assemblies begins our Key Customer Program and drives our Fully Enzymatic Synthesis technology to commercialization."
  • Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products.

Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis

Retrieved on: 
Mardi, août 2, 2022
DNA, NGS, Food, Time, GLOBE, Terminal deoxynucleotidyl transferase, U.S. Securities and Exchange Commission, Reading, Enzyme, SAN, SEC, Electronics, CEO, Research, Partnership, Private Securities Litigation Reform Act, Health, CRISPR, Oligonucleotide, NASDAQ, Gene, Rhode Island Division of Commercial Licensing and Regulation, Molecular assembler, Technology, Security (finance), Precision medicine, FES, Therapy, Annual report, Program, Gene editing, Synthetic biology, Fine chemical, Codexis

The optimized enzyme, deployed in Molecular Assemblies FES platform, is differentiated over natural enzymes on the ability to synthesize oligonucleotides of high yield and purity both critical for commercial success.

Key Points: 
  • The optimized enzyme, deployed in Molecular Assemblies FES platform, is differentiated over natural enzymes on the ability to synthesize oligonucleotides of high yield and purity both critical for commercial success.
  • This commercial license and supply agreement puts Molecular Assemblies in a position to achieve our commercialization objectives ahead of schedule.
  • The financial terms of the agreement include milestone payments from Molecular Assemblies to Codexis and royalties on sales of oligonucleotides synthesized using FES technology.
  • Under the terms of the agreement, Molecular Assemblies has exclusively licensed the Codexis evolved TdT enzyme for commercial use in DNA synthesis.

Molecular Assemblies Announces Jeffrey Sampson Joins Its Board of Directors

Retrieved on: 
Mercredi, juin 8, 2022
Leadership, ESP, Precision medicine, Company, Program, Intellectual property, Board of directors, Molecular assembler, Associate, Electronics, CEO, Multimedia, Agilent Technologies, FES, Technology, DNA, Acquisition, Director, SAN, Reading, Board, Synthetic biology, Assembly, Fine chemical, Management

SAN DIEGO, June 8, 2022 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the appointment of Jeffrey R. Sampson, Ph.D., to its Board of Directors.

Key Points: 
  • SAN DIEGO, June 8, 2022 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the appointment of Jeffrey R. Sampson, Ph.D., to its Board of Directors.
  • Molecular Assemblies also announced that David Hwang, who has served on the Company's board since 2019, has stepped down.
  • "On behalf of the Board and leadership of Molecular Assemblies, I would like to thank David for his dedicated and valuable service to the Company and wish him well in his future endeavors," said Larry Stambaugh, Chairperson of the Board of Directors.
  • For select researchers, Molecular Assemblies is providing early access to its Fully Enzymatic Synthesis (FES) technology through a Key Customer Program.

Global DNA Digital Data Storage Market Forecast Report 2021-2028 - Growing Demand for Long-Term Data Storage & Increasing Applications of DNA Data Storage - ResearchAndMarkets.com

Retrieved on: 
Lundi, avril 25, 2022
Technology, Genetics, Health, Data Management, Microsoft, Adoption, DNA, Western Digital, COVID-19, Agilent Technologies, CAGR, Growth, DNA Data Bank of Japan, Geography, Illumina, Inc., Molecular assembler, Health, Synthomer, PFU, Food security, Computer data storage

The "DNA Digital Data Storage Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sequencing; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "DNA Digital Data Storage Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sequencing; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • Over the past few years, advances in DNA digital data storage products have been making constant headlines.
  • The US has various players operating in the global DNA digital data storage market.
  • Thus, the presence and active involvement of market players are propelling the adoption of DNA digital storage, further driving the growth of the DNA digital data storage market.

Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis

Retrieved on: 
Mardi, avril 12, 2022
CEO, Biology, DNA, U.S. Securities and Exchange Commission, Codexis, Security (finance), Research, Â, Enzyme, Annual report, Private Securities Litigation Reform Act, NGS, GLOBE, Program, Gene editing, SAN, Conference, Efficiency, Electronics, Food, Technology, Barrier, Solution, Reading, SEC, Assembly, Terminal deoxynucleotidyl transferase, Gene, Partnership, Molecular assembler, Health, CRISPR, Precision medicine, Therapy, FES, Synthetic biology, Fine chemical

REDWOOD CITY, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced an update on their partnership to engineer enzymes to deliver differentiated solutions for the enzymatic synthesis of DNA. Using a highly evolved DNA polymerase, developed by Codexis, to enable its Fully Enzymatic Synthesis™ (or FES™) technology, select companies and institutions will be able to access a Key Customer Program that is slated to begin later this year.

Key Points: 
  • The Fully Enzymatic Synthesis technology developed by Molecular Assemblies employs a template-independent DNA polymerase, terminal deoxynucleotidyl transferase (TdT), which has the ability to synthesize much longer DNA sequences with fewer errors in an aqueous solution.
  • In order to accelerate innovation for the field, Molecular Assemblies and Codexis partnered in 2020 to engineer an enzyme to deliver differentiated and cost-effective solutions for the fully enzymatic synthesis of DNA.
  • We believe the ability to exclusively deploy this proprietary enzyme will significantly differentiate Molecular Assemblies Fully Enzymatic Synthesis technology from not only other emerging players but also the current industry-standard phosphoramidite chemistry method.
  • Scientists at Molecular Assemblies have developed a Fully Enzymatic Synthesis technology that produces highly pure, sequence-specific DNA on demand.

Molecular Assemblies Announces $25.8 Million Series B Financing to Initiate Key Customer Program for Commercial Access to Fully Enzymatic DNA Synthesis

Retrieved on: 
Mardi, mars 15, 2022
Technology, Agriculture, Enzyme, Therapy, Multimedia, Protein, DNA synthesis, Series, Senior, Agilent Technologies, Terminal deoxynucleotidyl transferase, Reading, Principal, CEO, Synthetic biology, Electronics, Precision medicine, FES, Efficiency, SAN, DNA, Gene, CRISPR, Fine chemical, Codexis, Molecular assembler

The proceeds of the financing will be used to advance the company's proprietary enzymatic DNA synthesis technology toward early commercialization and start a key customer program later this year.

Key Points: 
  • The proceeds of the financing will be used to advance the company's proprietary enzymatic DNA synthesis technology toward early commercialization and start a key customer program later this year.
  • "Molecular Assemblies is a pioneer in the field of enzymatic DNA synthesis, and our additional investment in the company underscores our support for their approach, team, and technology."
  • Scientists at Molecular Assemblies have developed a Fully Enzymatic Synthesis (or FES) technology that produces highly pure, sequence-specific DNA on demand.
  • I look forward to Molecular Assemblies exclusively deploying this proprietary enzyme to unlock the enormous commercial potential of enzymatic DNA synthesis."